Patents by Inventor Wei Ling Wang
Wei Ling Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11542274Abstract: There are provided new heterobifunctional agents designed to mediated formation of protein-protein dimers and promote ubiquitination of a protein of the dimer. Also provided are methods of synthesizing the agents, pharmaceutical formulations including the agents, and methods of using the agents to treat, ameliorate or cure diseases characterized by protein over-expression or malfunction.Type: GrantFiled: September 23, 2021Date of Patent: January 3, 2023Assignee: Agency for Science, Technology and Research (A*STAR)Inventors: Wei Hung, Thomas Hugo Keller, Wei Ling Wang, Gang Wang, Congbao Kang
-
Patent number: 11434245Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein.Type: GrantFiled: October 29, 2020Date of Patent: September 6, 2022Assignee: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20210147441Abstract: There are provided new heterobifuctional agents designed to mediated formation of protein-protein dimers and promote ubiqutination of a protein of the dimer. Also provided are methods of synthesizing the agents, pharmaceutical formulations including the agents, and methods of using the agents to treat, ameliorate or cure diseases characterized by protein over-expression or malfunction.Type: ApplicationFiled: September 22, 2020Publication date: May 20, 2021Inventors: Wei Hung, Thomas Hugo Keller, Wei Ling Wang, Gang Wang, Congbao Kang
-
Publication number: 20210047336Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R1 represents H; optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy, NH2, —NHC1-3alkyl and —N(C1-3alkyl)2); —C(O)Oalkyl; haloalkyl; haloalkoxy; or -alkylaryl; each R2 independently represents H; optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy, NH2, —NHC1-3alkyl and —N(C1-3alkyl)2); -alkylaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independentlType: ApplicationFiled: October 29, 2020Publication date: February 18, 2021Applicant: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Patent number: 10870653Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein each of R1, R2, R3, R4, R5, W, X, Y, Z, and n is as defined herein.Type: GrantFiled: December 19, 2018Date of Patent: December 22, 2020Assignee: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20190185478Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R1 represents H; optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy, NH2, —NHC1-3alkyl and —N(C1-3alkyl)2); —C(O)Oalkyl; haloalkyl; haloalkoxy; or -alkylaryl; each R2 independently represents H; optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy, NH2, —NHC1-3alkyl and —N(C1-3alkyl)2); -alkylaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); optionally substituted heterocyclyl (wherein optional substituents include one or more substituents each independentlType: ApplicationFiled: December 19, 2018Publication date: June 20, 2019Applicant: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Patent number: 10300586Abstract: A screw holding and dispensing device includes a casing, a number of elastic members latched on an inner sidewall of the casing, and a pressing member received by the elastic member. Each elastic member carries a screw, to release a screw, an external force is applied on the pressing member, the pressing member is driven to move out of the top elastic member, the pressing member moves down and drives out the lowermost screw from the bottom elastic member, and the screw slides into a corresponding screw hole.Type: GrantFiled: May 26, 2017Date of Patent: May 28, 2019Assignees: Fu Tai Hua Industry (Shenzhen) Co., Ltd., HON HAI PRECISION INDUSTRY CO., LTD.Inventor: Wei-Ling Wang
-
Patent number: 10189842Abstract: The present invention relates to dihydropyrazolo[1,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.Type: GrantFiled: December 17, 2014Date of Patent: January 29, 2019Assignee: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Patent number: 9981964Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R1 represents optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy); optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or -alkylaryl; R2 represents H; or alkyl; R3 represents H; or alkyl; U, V and W represent —(CH2)—; or U and V together represent —CH?CH— and W represents C?O; Y represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or optionally substituted heterocyclyl (wherein optiType: GrantFiled: December 17, 2014Date of Patent: May 29, 2018Assignee: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Anders Poulsen, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20180093988Abstract: The present invention relates to dihydropyrazolo[1,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.Type: ApplicationFiled: December 17, 2014Publication date: April 5, 2018Applicant: Agency for Science, Technolgy and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20170341207Abstract: A screw holding and dispensing device includes a casing, a number of elastic members latched on an inner sidewall of the casing, and a pressing member received by the elastic member. Each elastic member carries a screw, to release a screw, an external force is applied on the pressing member, the pressing member is driven to move out of the top elastic member, the pressing member moves down and drives out the lowermost screw from the bottom elastic member, and the screw slides into a corresponding screw hole.Type: ApplicationFiled: May 26, 2017Publication date: November 30, 2017Inventor: WEI-LING WANG
-
Publication number: 20170240550Abstract: The present invention relates to dihydropyrazolo[1,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.Type: ApplicationFiled: December 17, 2014Publication date: August 24, 2017Applicant: Agency for Science, Technolgy and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20160318926Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R1 represents optionally substituted alkyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkoxy); optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or -alkylaryl; R2 represents H; or alkyl; R3 represents H; or alkyl; U, V and W represent —(CH2)—; or U and V together represent —CH?CH— and W represents C?O; Y represents aryl; heteroaryl; optionally substituted carbocyclyl (wherein optional substituents include one or more substituents each independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, C1-6haloalkoxy and halo); or optionally substituted heterocyclyl (wherein optiType: ApplicationFiled: December 17, 2014Publication date: November 3, 2016Applicant: Agency for Science, Technology and ResearchInventors: Jenefer Alam, Anders Poulsen, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy
-
Publication number: 20160311829Abstract: The present invention relates to dihydropyrazolo[1,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.Type: ApplicationFiled: December 17, 2014Publication date: October 27, 2016Applicant: Agency for Science, Technolgy and ResearchInventors: Jenefer Alam, Soo Yei Ho, Wei Ling Wang, Athisayamani Jeyaraj Duraiswamy